(NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO ® (naloxone HCl) Nasal Spray ...
Under the terms of the six-year agreement, Emergent will add KLOXXADO® Nasal Spray to its naloxone product portfolio and will be responsible for all North America product sales and marketing.
Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...
Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...
Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...
Emergent distributes NARCAN® Nasal Spray 4 mg, which is the first FDA-approved over-the-counter naloxone product for the emergency treatment of opioid overdose. Under the terms of the six-year ...